T-Cell Leukemia - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：79頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
T-Cell Leukemia - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘T-Cell Leukemia - Pipeline Review, H1 2014’, provides an overview of the T-Cell Leukemia’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for T-Cell Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for T-Cell Leukemia and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of T-Cell Leukemia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for T-Cell Leukemia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the T-Cell Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the T-Cell Leukemia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for T-Cell Leukemia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding T-Cell Leukemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘T-Cell Leukemia - Pipeline Review, H1 2014’, provides an overview of the T-Cell Leukemia’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for T-Cell Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for T-Cell Leukemia and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of T-Cell Leukemia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for T-Cell Leukemia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the T-Cell Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the T-Cell Leukemia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for T-Cell Leukemia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding T-Cell Leukemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
T-Cell Leukemia Overview 8
Therapeutics Development 9
Pipeline Products for T-Cell Leukemia - Overview 9
Pipeline Products for T-Cell Leukemia - Comparative Analysis 10
T-Cell Leukemia - Therapeutics under Development by Companies 11
T-Cell Leukemia - Therapeutics under Investigation by Universities/Institutes 13
T-Cell Leukemia - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
T-Cell Leukemia - Products under Development by Companies 17
T-Cell Leukemia - Products under Investigation by Universities/Institutes 18
T-Cell Leukemia - Companies Involved in Therapeutics Development 19
Bristol-Myers Squibb Company 19
Kyowa Hakko Kirin Co., Ltd. 20
Nippon Kayaku Co., Ltd. 21
Pfizer Inc. 22
Celgene Corporation 23
Mundipharma International Limited 24
Pharmacyclics, Inc. 25
Stemline Therapeutics, Inc. 26
CytImmune Sciences, Inc. 27
Applied Immune Technologies Ltd 28
T-Cell Leukemia - Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Target 30
Assessment by Mechanism of Action 33
Assessment by Route of Administration 36
Assessment by Molecule Type 38
Drug Profiles 40
mogamulizumab - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
mogamulizumab - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
forodesine hydrochloride - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
lenalidomide - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Anti-Tac(Fv)-PE38 Immunotoxin - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
PF-03084014 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
BMS-906024 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
PCI-34051 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
SL-101 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Lenaldekar - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
CYT-91000 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
NK-314 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Immunotoxins - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
TCRL Antibodies For HTLV-1 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
L1AD3 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
T-Cell Leukemia - Recent Pipeline Updates 61
T-Cell Leukemia - Dormant Projects 71
T-Cell Leukemia - Discontinued Products 72
T-Cell Leukemia - Product Development Milestones 73
Featured News & Press Releases 73
Dec 07, 2013: Infinity Reports Preclinical Data at ASH Annual Meeting in Diffuse Large B-Cell Lymphoma and T-Cell Acute Lymphoblastic Leukemia Suggesting Broad Potential of IPI-145 in Blood Cancers 73
Aug 23, 2012: Kyowa Hakko Kirin Initiates Pivotal Phase II Trial Of Mogamulizumab In Patients With Adult T-cell Leukemia-Lymphoma In US And Europe 74
Jul 19, 2012: Application Seeking Approval for Additional Indication for ATL, PTCL and CTCL of Mogamulizumab 75
May 29, 2012: Kyowa Hakko Kirin Launches POTELIGEO Injection In Japan 75
Apr 09, 2012: Study Demonstrates Potential Of New Anti-Leukemia Compound, Lenaldekar 75
Dec 07, 2010: Kyowa Hakko Kirin Announces Results From Japan Phase II Clinical Trial Of KW-0761 In Adult T-Cell Leukemia-Lymphoma 76
Appendix 78
Methodology 78
Coverage 78
Secondary Research 78
Primary Research 78
Expert Panel Validation 78
Contact Us 79
Disclaimer 79
List of Tables
Number of Products under Development for T-Cell Leukemia, H1 2014 9
Number of Products under Development for T-Cell Leukemia - Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 12
Number of Products under Investigation by Universities/Institutes, H1 2014 13
Comparative Analysis by Late Stage Development, H1 2014 14
Comparative Analysis by Clinical Stage Development, H1 2014 15
Comparative Analysis by Early Stage Development, H1 2014 16
Products under Development by Companies, H1 2014 17
Products under Investigation by Universities/Institutes, H1 2014 18
T-Cell Leukemia - Pipeline by Bristol-Myers Squibb Company, H1 2014 19
T-Cell Leukemia - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2014 20
T-Cell Leukemia - Pipeline by Nippon Kayaku Co., Ltd., H1 2014 21
T-Cell Leukemia - Pipeline by Pfizer Inc., H1 2014 22
T-Cell Leukemia - Pipeline by Celgene Corporation, H1 2014 23
T-Cell Leukemia - Pipeline by Mundipharma International Limited, H1 2014 24
T-Cell Leukemia - Pipeline by Pharmacyclics, Inc., H1 2014 25
T-Cell Leukemia - Pipeline by Stemline Therapeutics, Inc., H1 2014 26
T-Cell Leukemia - Pipeline by CytImmune Sciences, Inc., H1 2014 27
T-Cell Leukemia - Pipeline by Applied Immune Technologies Ltd, H1 2014 28
Assessment by Monotherapy Products, H1 2014 29
Number of Products by Stage and Target, H1 2014 32
Number of Products by Stage and Mechanism of Action, H1 2014 35
Number of Products by Stage and Route of Administration, H1 2014 37
Number of Products by Stage and Molecule Type, H1 2014 39
T-Cell Leukemia Therapeutics - Recent Pipeline Updates, H1 2014 61
T-Cell Leukemia - Dormant Projects, H1 2014 71
T-Cell Leukemia - Discontinued Products, H1 2014 72
List of Figures
Number of Products under Development for T-Cell Leukemia, H1 2014 9
Number of Products under Development for T-Cell Leukemia - Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 11
Number of Products under Investigation by Universities/Institutes, H1 2014 13
Comparative Analysis by Clinical Stage Development, H1 2014 15
Comparative Analysis by Early Stage Products, H1 2014 16
Assessment by Monotherapy Products, H1 2014 29
Number of Products by Top 10 Target, H1 2014 30
Number of Products by Stage and Top 10 Target, H1 2014 31
Number of Products by Top 10 Mechanism of Action, H1 2014 33
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 34
Number of Products by Top 10 Route of Administration, H1 2014 36
Number of Products by Stage and Top 10 Route of Administration, H1 2014 37
Number of Products by Top 10 Molecule Type, H1 2014 38
Number of Products by Stage and Top 10 Molecule Type, H1 2014 39
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
T-Cell Leukemia Overview 8
Therapeutics Development 9
Pipeline Products for T-Cell Leukemia - Overview 9
Pipeline Products for T-Cell Leukemia - Comparative Analysis 10
T-Cell Leukemia - Therapeutics under Development by Companies 11
T-Cell Leukemia - Therapeutics under Investigation by Universities/Institutes 13
T-Cell Leukemia - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
T-Cell Leukemia - Products under Development by Companies 17
T-Cell Leukemia - Products under Investigation by Universities/Institutes 18
T-Cell Leukemia - Companies Involved in Therapeutics Development 19
Bristol-Myers Squibb Company 19
Kyowa Hakko Kirin Co., Ltd. 20
Nippon Kayaku Co., Ltd. 21
Pfizer Inc. 22
Celgene Corporation 23
Mundipharma International Limited 24
Pharmacyclics, Inc. 25
Stemline Therapeutics, Inc. 26
CytImmune Sciences, Inc. 27
Applied Immune Technologies Ltd 28
T-Cell Leukemia - Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Target 30
Assessment by Mechanism of Action 33
Assessment by Route of Administration 36
Assessment by Molecule Type 38
Drug Profiles 40
mogamulizumab - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
mogamulizumab - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
forodesine hydrochloride - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
lenalidomide - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Anti-Tac(Fv)-PE38 Immunotoxin - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
PF-03084014 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
BMS-906024 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
PCI-34051 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
SL-101 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Lenaldekar - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
CYT-91000 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
NK-314 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Immunotoxins - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
TCRL Antibodies For HTLV-1 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
L1AD3 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
T-Cell Leukemia - Recent Pipeline Updates 61
T-Cell Leukemia - Dormant Projects 71
T-Cell Leukemia - Discontinued Products 72
T-Cell Leukemia - Product Development Milestones 73
Featured News & Press Releases 73
Dec 07, 2013: Infinity Reports Preclinical Data at ASH Annual Meeting in Diffuse Large B-Cell Lymphoma and T-Cell Acute Lymphoblastic Leukemia Suggesting Broad Potential of IPI-145 in Blood Cancers 73
Aug 23, 2012: Kyowa Hakko Kirin Initiates Pivotal Phase II Trial Of Mogamulizumab In Patients With Adult T-cell Leukemia-Lymphoma In US And Europe 74
Jul 19, 2012: Application Seeking Approval for Additional Indication for ATL, PTCL and CTCL of Mogamulizumab 75
May 29, 2012: Kyowa Hakko Kirin Launches POTELIGEO Injection In Japan 75
Apr 09, 2012: Study Demonstrates Potential Of New Anti-Leukemia Compound, Lenaldekar 75
Dec 07, 2010: Kyowa Hakko Kirin Announces Results From Japan Phase II Clinical Trial Of KW-0761 In Adult T-Cell Leukemia-Lymphoma 76
Appendix 78
Methodology 78
Coverage 78
Secondary Research 78
Primary Research 78
Expert Panel Validation 78
Contact Us 79
Disclaimer 79
List of Tables
Number of Products under Development for T-Cell Leukemia, H1 2014 9
Number of Products under Development for T-Cell Leukemia - Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 12
Number of Products under Investigation by Universities/Institutes, H1 2014 13
Comparative Analysis by Late Stage Development, H1 2014 14
Comparative Analysis by Clinical Stage Development, H1 2014 15
Comparative Analysis by Early Stage Development, H1 2014 16
Products under Development by Companies, H1 2014 17
Products under Investigation by Universities/Institutes, H1 2014 18
T-Cell Leukemia - Pipeline by Bristol-Myers Squibb Company, H1 2014 19
T-Cell Leukemia - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2014 20
T-Cell Leukemia - Pipeline by Nippon Kayaku Co., Ltd., H1 2014 21
T-Cell Leukemia - Pipeline by Pfizer Inc., H1 2014 22
T-Cell Leukemia - Pipeline by Celgene Corporation, H1 2014 23
T-Cell Leukemia - Pipeline by Mundipharma International Limited, H1 2014 24
T-Cell Leukemia - Pipeline by Pharmacyclics, Inc., H1 2014 25
T-Cell Leukemia - Pipeline by Stemline Therapeutics, Inc., H1 2014 26
T-Cell Leukemia - Pipeline by CytImmune Sciences, Inc., H1 2014 27
T-Cell Leukemia - Pipeline by Applied Immune Technologies Ltd, H1 2014 28
Assessment by Monotherapy Products, H1 2014 29
Number of Products by Stage and Target, H1 2014 32
Number of Products by Stage and Mechanism of Action, H1 2014 35
Number of Products by Stage and Route of Administration, H1 2014 37
Number of Products by Stage and Molecule Type, H1 2014 39
T-Cell Leukemia Therapeutics - Recent Pipeline Updates, H1 2014 61
T-Cell Leukemia - Dormant Projects, H1 2014 71
T-Cell Leukemia - Discontinued Products, H1 2014 72
List of Figures
Number of Products under Development for T-Cell Leukemia, H1 2014 9
Number of Products under Development for T-Cell Leukemia - Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 11
Number of Products under Investigation by Universities/Institutes, H1 2014 13
Comparative Analysis by Clinical Stage Development, H1 2014 15
Comparative Analysis by Early Stage Products, H1 2014 16
Assessment by Monotherapy Products, H1 2014 29
Number of Products by Top 10 Target, H1 2014 30
Number of Products by Stage and Top 10 Target, H1 2014 31
Number of Products by Top 10 Mechanism of Action, H1 2014 33
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 34
Number of Products by Top 10 Route of Administration, H1 2014 36
Number of Products by Stage and Top 10 Route of Administration, H1 2014 37
Number of Products by Top 10 Molecule Type, H1 2014 38
Number of Products by Stage and Top 10 Molecule Type, H1 2014 39
